St Lawrence County Police Protection · Executive Office · General Government · Individual/Family Services Executive Office · Urban/Community Development · Indvdlfmly Svcs · Court · Public Finance/Taxation/Monetary Policy
- Cambridge MA, US Thomas Schurpf - Cambridge MA, US Adam Fogel - Cambridge MA, US Christopher Brueckner - Cambridge MA, US Alan Buckler - Cambridge MA, US Constance Martin - Cambridge MA, US Si Tuen Lee-Hoeflich - Cambridge MA, US
International Classification:
C07K 16/22 C07K 16/28 A61P 35/00
Abstract:
The present disclosure provides TGFβ inhibitor therapy for treating immunosuppressive conditions, such as cancer. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.
High-Affinity, Isoform-Selective Tgfß1 Inhibitors And Use Thereof
- Cambridge MA, US Allan Capili - Somerville MA, US Thomas Schurpf - Cambridge MA, US Constance Martin - Arlington MA, US Kevin B. Dagbay - Brighton MA, US Christopher Chapron - Watertown MA, US Stefan Wawersik - Westborough MA, US Christopher Littlefield - Marblehead MA, US Gregory J. Carven - Maynard MA, US Alan Buckler - Arlington MA, US Susan Lin - Boston MA, US Justin W. Jackson - Cambridge MA, US Caitlin Stein - Lebanon NH, US Andrew Avery - Lebanon NH, US Anthony Cooper - White River Junction VT, US Matthew Salotto - Hanover NH, US
International Classification:
C07K 16/22 A61K 45/06 A61P 35/00
Abstract:
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
- Cambridge MA, US Gregory J. Carven - Maynard MA, US Stefan Wawersik - Westborough MA, US Thomas Schurpf - Cambridge MA, US Constance Martin - Arlington MA, US Abhishek Datta - Boston MA, US Mark Allen Farmer - North Reading MA, US
International Classification:
C07K 16/22 A61P 35/04 A61P 35/02
Abstract:
Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells.
Isoform-Selective Tgfb1 Inhibitors And Use Thereof
- Cambridge MA, US Allan Capili - Somerville MA, US Thomas Schurpf - Cambridge MA, US Constance Martin - Arlington MA, US Kevin B. Dagbay - Brighton MA, US Christopher Chapron - Watertown MA, US Stefan Wawersik - Westborough MA, US Christopher Littlefield - Marblehead MA, US Gregory J. Carven - Maynard MA, US Alan Buckler - Arlington MA, US Susan Lin - Boston MA, US Justin W. Jackson - Cambridge MA, US
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
Ms. Martin works in Cincinnati, OH and specializes in Pediatric Otolaryngology. Ms. Martin is affiliated with Cincinnati Childrens Hospital Medical Center, Good Samaritan Hospital, Shriners Hospitals For Children Cincinnati and UC Medical Center.